Abstract
Extracellular vesicles (EVs)-based therapeutics are based on the premise that EVs shed by stem cells exert similar therapeutic effects and these have been proposed as an alternative to cell therapies. EV-mediated delivery is an effective and efficient system of cell-to-cell communication which can confer therapeutic benefits to their target cells. EVs have been shown to promote tissue repair and regeneration in various animal models such as, wound healing, cardiac ischemia, diabetes, lung fibrosis, kidney injury, and many others. Given the unique attributes of EVs, considerable thought must be given to the preservation, formulation and cold chain strategies in order to effectively translate exciting preclinical observations to clinical and commercial success. This review summarizes current understanding around EV preservation, challenges in maintaining EV quality, and also bioengineering advances aimed at enhancing the long-term stability of EVs.
Introduction
Interest in extracellular vesicles (EVs) has escalated over the last decade. This has been particularly the case in clinical applications, including the application of EV biology to biomarker discovery, vaccine development, drug delivery, and EV-based therapeutics. EVs are key players in intercellular communication and they are protected from degradation by their lipid bilayer membrane that envelop bioactive cargo. These include proteins, sugars, lipids, and nucleic acids. EVs can be classified based on their size, i.e., apoptotic bodies (>1000 nm), microvesicles (100 – 1000 nm), and exosomes (30 – 150 nm) (Kalra et al., 2016; Tkach and Théry, 2016). The field of EV research is rapidly gaining momentum and overlaps with the newer field of bioengineering where synthetic liposomes, biomimetic vesicles, and nanoparticles have been utilized to package bioactive cargo. In this review, we assess current strategies employed for EV preservation and bioengineering advances aimed at enhancing long term stability of EVs intended for clinical use.
Composition and Cargo of EVs
Extracellular vesicles are ideal intercellular transporters of biomolecules. They express surface molecules that enable tissue- or cell-specific targeting. Upon reaching their recipient cells, EVs can induce signaling via receptor-ligand interaction, or be internalized by endocytosis to deliver their cargo. The term “exosomes” is generally used to describe most EVs globally. In an attempt to standardize nomenclature and improve accuracy of data interpretation, the International Society of Extracellular Vesicles (ISEV) published a set of guidelines in 2014 that outlined the so-called minimal requirements to define EVs (Lötvall et al., 2014). The collective term of EVs will be used throughout this review since the definition of exosomes remains contentious. Given the increasing interest in EVs and their potential use in regenerative medicine, isolated EVs must be carefully characterized – this necessarily requires a complex combination of protein profiling (proteomics, western blotting, or flow cytometry), imaging, and nanoparticle tracking analysis.
Extracellular vesicles are secreted by virtually all cell types and present in all bodily fluids. An online public database, ExoCarta1 (Keerthikumar et al., 2016) has been created to curate this diverse body of data, with the goal of facilitating and encouraging collaborative research. This public repository is being continuously updated with new contributions from various EV researchers.
Extracellular vesicles are enriched in membrane proteins and cellular proteins, including the tetraspanins CD63, CD9, CD81, Alix, Tsg101, MHC1 and heat shock proteins (van Niel et al., 2006; Raposo and Stoorvogel, 2013). The protein cargo of EVs include cell-specific proteins which are responsible for specific fates and functions, such as: cell adhesion (integrins, ICAM), signal transductions (G proteins, β-catenin, protein kinases), and intracellular trafficking (RAB, GTPases, annexins) (van Niel et al., 2018). The lipid contents of EVs include ceramides, sphingomyelins, phosphatidylserine, and cholesterol (Laulagnier et al., 2004; Subra et al., 2007). This unique lipid composition is thought to facilitate the uptake of EVs by recipient cells. The lipid composition of EV membranes also play significant roles in intercellular signaling and provide structural stability (Skotland et al., 2017). Furthermore, the surfaces of EVs are surrounded by polysaccharides and glycan (Batista et al., 2011). The nucleic acid cargo in EVs such as mitochondrial DNA, genomic DNA, mRNA, miRNA, and long non-coding RNA have already been documented extensively. Importantly, exosomal RNA play functional roles in EV-mediated cellular communication where exosomal mRNA can be translated into proteins in recipient cells and exosomal microRNA (miR) may regulate gene expression in recipient cells (Valadi et al., 2007).
EVs Molecular Cargo Involved in Therapeutic Benefits/Immunomodulation
EV-mediated delivery is an effective and efficient system to confer therapeutic benefits to their target destinations. The contents of EV cargo can be heavily influenced by their producer cells and different cell types will secrete a range of functional effects on recipient cells. The ability of EVs to interact with recipient cells is likely to be affected by the presence of adhesion molecules (e.g., integrins) on the surface of EVs, and this will contribute to the cell or tissue specificity of EVs (van Niel et al., 2018).
Extracellular vesicles exhibit intrinsic therapeutic benefits, for example, EVs can be used as gene delivery vehicles without inducing adverse immune reactions. This contrasts with the more commonly used gene therapy vehicles such as viral vectors and lipid nanoparticles which are immunogenic (Kumar et al., 2014).
There are a number of different strategies to identify and validate EV-mediated cargo delivery into recipient cells. For example, labeling EVs with a tracking dye can result in a quantifiable increase in fluorescence in the recipient cells once exosome uptake occurs. Alternatively, EV-associated RNA labeled with a radioactive tracer can be used to demonstrate uptake by recipient cells (Valadi et al., 2007). For the purposes of this review, we have summarized recent studies describing the therapeutic use of EVs from human cell types in Table 1.
Table 1
| EV cargo | EV source | Recipient | Therapeutic claim | Reference |
|---|---|---|---|---|
| Proteins | ||||
| Peptide-MHC complexes | Dendritic cells pulsed with diphtheria toxin | Mice | Induced diphtheria-toxin antibody production | Colino and Snapper, 2006 |
| APOBEC3G (antiviral protein) | Human CD4+ T cells | Jurkat T cells | Resistance to HIV | Khatua et al., 2009 |
| Fas | hBMMSCs | Fas-deficient mice | Ameliorated osteopenia | Liu et al., 2015 |
| EMMPRIN | CMPCs and MSCs | HMECs and HUVECs | Increased angiogenesis and endothelial cell migration | Vrijsen et al., 2016 |
| AT1R | HEK293T cells | Mice | Modulated blood pressure | Pironti et al., 2015 |
| Dll4 | U87GM and HUVECs | HUVECs | Increased Notch signaling and angiogenesis | Sheldon et al., 2010 |
| MHC class I and II | B cells | T cells | Induced T cell proliferation and TH2-like cytokine production | Admyre et al., 2007 |
| Cystinosin (and CTNS mRNA) | hAMMSCs and hBMMSCs | Cystinotic fibroblasts | Reduced cystine accumulation | Iglesias et al., 2012 |
| Neprilysin | hADMSCs | Mouse neuroblastoma cells | Decreased intracellular β–amyloid peptide | Katsuda et al., 2013 |
| CD73 | hBMMSCs | GVHD mice | Promoted adenosine-based immunosuppression | Amarnath et al., 2015 |
| Nucleic acids | ||||
| mtDNA | hBMMSCs | Macrophages | Reduced mitochondrial ROS generation | Phinney et al., 2015 |
| lncRNA | Hela cells | C33A cells | Enhanced cell viability | Hewson et al., 2016 |
| mRNA (Wnt4) | UC-MSCs | Mice | Accelerated wound re-epithelisation and cell proliferation | Zhang et al., 2015a |
| mRNA (IL-10) | hBMMSCs and UC-MSCs | Kidney tubular cells | Increased cell recovery following injury | Ragni et al., 2016 |
| mRNA (IGF-1R) | hBMMSCs | Cisplatin-damaged PTECs | Enhanced cell proliferation | Tomasoni et al., 2013 |
| miR-150 | Monocytes | Endothelial cells | Promote angiogenesis | Li et al., 2013 |
| miR-143, miR-145 | Endothelial cells | Aortic SMCs | Reduced atherosclerotic lesions | Hergenreider et al., 2012 |
| Let-7c | hMSCs | Mice | Reduced renal fibrosis | Wang et al., 2016 |
| miR-21, miR-210 | iPSCs | Cardiomyocytes | Rescued ischemic cardiomyocytes | Wang et al., 2015 |
| miR-146a | hMSCs | Macrophages | M2 polarization and increased survival in septic mice | Song et al., 2017 |
| miR-21-3p | UCB plasma | Mice | Enhanced angiogenesis and promoted wound healing | Hu et al., 2018 |
| miR-22 | hMSCs | Cardiomyocytes | Improved cardiac function | Feng et al., 2014 |
| miR-1343 | HL-60 neutrophil-like cells | Lung fibroblasts | Inhibition of TGF-β signaling and myofibroblast differentiation | Stolzenburg and Harris, 2017 |
| miR-100 | hMSCs | Breast cancer cells | Suppression of angiogenesis and downregulation of VEGF | Pakravan et al., 2017 |
| miR-19a | hMSCs | Cardiomyocytes | Restored cardiac contractile function and reduced infarct size | Yu et al., 2015 |
| miR-21-5p | hMSCs | iPSCs-derived cardiomyocytes and iPSCs-derived fibroblasts | Increased engineered cardiac tissue contractility via PI3K signaling | Mayourian et al., 2018 |
| miR-126, miR-296 | EPCs | Islet endothelium | Increased angiogenesis and revascularisation of islets | Cantaluppi et al., 2012 |
| miR-146a | CDCs | Injured mouse hearts | Inhibited apoptosis, promote cardiomyocytes proliferation and angiogenesis | Ibrahim et al., 2014 |
| miR-196a | hBMMSCs | Rats with calvarial bone defects | Stimulated bone formation | Qin et al., 2016 |
| miR-23b | hBMMSCs | Human breast cancer cell line | Induced dormant phenotype | Ono et al., 2014 |
| miR-125a | hADMSCs | HUVECs | Promoted angiogenesis | Liang et al., 2016 |
| miR-122 | hADMSCs | Hepatocellular carcinoma cells | Increased sensitivity to chemotherapeutic agents | Lou et al., 2015 |
Individual human-derived EVs cargo components and their therapeutic effects.
EMMPRIN, extracellular matrix metalloproteinase inducer; CMPCs, cardiomyocyte progenitor cells; HMECs, human microvascular endothelial cells; HUVECs, human umbilical vein endothelial cells; AT1R, angiotensin II type I receptor; Dll4, Delta-like 4 Notch ligand; hAMMSCs, human amniotic mesenchymal stem cells; hBMMSCs, human bone marrow MSCs; hADMSCs, human adipose tissue MSCs; mtDNA, mitochondrial DNA; UC-MSCs, umbilical cord MSCs; PTECs, proximal tubular epithelial cells; SMCs, smooth muscle cells; iPSCs, induced pluripotent stem cells; UCB, umbilical cord blood; EPCs, endothelial progenitor cells; CDCs, cardiosphere-derived cells.
EV-based therapeutics have been proposed as an alternative to cellular therapy, where the latter refers to the use of intact, living cells. In particular, cell therapy exploits the ability of the cellular products to secrete a complex repertoire of bioactive factors including EVs. However, the widespread use of cell therapies has been limited by challenges in the scalability and reproducibility of cell manufacturing. A paradigm shift toward cell-free therapies has now captured the attention of this sector, where the potential of EVs is being explored (Gnecchi et al., 2016; Kusuma et al., 2017). In comparison to cells, EVs have a simplified cold chain process, and have a lower risk profile due to the unlikelihood of spontaneous DNA transformation or immune rejection. Furthermore, EVs can be used directly, either alone or in combination with other pharmacological agents (Fais et al., 2016).
EV-Based Therapeutics
Preclinical Evaluation of EV-Based Therapeutics
Stem cell-derived EVs have been shown to modulate the immune response from both the innate and adaptive immunity. Favaro et al. (2014, 2016) showed that BMMSCs-EVs induced regulatory dendritic cell (DC) phenotypes with the ability to inhibit T cell activity, while ESC-EVs can reportedly promote M2 macrophage polarization, upregulate Treg numbers and downregulate splenocyte proliferation (Zhang et al., 2014a). Additionally, MSC-EVs were reported to promote Treg proliferation and inhibit autoreactive T cell activity (Del Fattore et al., 2015), as well as induce polymyxin-resistant MyD88-dependent secreted embryonic alkaline phosphatase expression in THP-1 cells (Zhang et al., 2014b). In a mouse model of myasthenia gravis, MSC-EVs reduced T cell-dependent immunoactivation, ameliorated autoimmune injury, and prolonged survival time (Sudres et al., 2017). Additionally, Shigemoto-Kuroda et al. (2017) showed that MSC-EVs modulate immune responses in two different autoimmune mouse models. In a mouse model of type I diabetes, they showed that MSC-EVs delayed the onset of type I diabetes through modulation of IL-1β mediated pancreatic B-cell destruction. Similarly, they showed that 30 μg of MSC-EVs attenuated uveoretinitis triggered by Th1/Th17 activation (Shigemoto-Kuroda et al., 2017).
In murine models of kidney injury, MSC-derived EVs protected against renal injury by reducing levels of creatinine, uric acid, lymphocyte response and fibrosis through shuttling miR-let7c to induce renal tubular cell proliferation (Wang et al., 2016). In a murine model of carbon tetrachloride-induced hepatic injury, concurrent treatments of MSC-EVs attenuated the injury by increasing the proliferation, survival and prevented the apoptosis of hepatocytes (Tan et al., 2014). In animal models of lung injury, MSC and hAEC-EVs have been shown to reduce pulmonary inflammation, improved lung tissue recovery and supported the proliferation of alveolar type II and bronchioalveolar stem cells (Rubenfeld et al., 2005; Cruz et al., 2015; Monsel et al., 2015; Tan et al., 2018). In models of stroke, MSC-EVs delivery of miR-133b directly to neurite cells reportedly enhanced the outgrowth of neurites resulting in increased proliferation of neuroblasts and endothelial cells (Xin et al., 2013). Additionally, Anderson et al. showed through a comprehensive proteomic analysis that MSC-derived EVs mediated angiogenesis via NF-κB signaling (Anderson et al., 2016), while Zhang et al. (2015b) showed that UC MSC-EVs mediated angiogenesis via the Wnt4/β-catenin pathway.
The possibility for EV-based therapeutics to be developed from immune cells is also currently being explored. EVs from dendritic cells have been engineered in various ways to help combat autoimmune diseases. These include stimulating DCs with IFNγ to express miRNAs which stimulate myelination, and reduce oxidative stress (Pusic et al., 2014). Immature DCs (iDCs)-EVs, which have not conformed to their mature role in expressing MHC and co-stimulatory molecules, displayed immunosuppressive properties in autoimmune diseases. For instance, in a mouse model of autoimmune neuromuscular disorder; myasthenia gravis (MG) iDC-derived EVs prevented MG disorder by suppressing lymphocyte reactivity in vivo (Bu et al., 2015). Immune cell-derived EVs are relatively easy to isolate and as such can be beneficial as potential targets for autoimmune and cancer treatments.
Clinical Application of EV-Based Therapeutics
There is currently only a handful of clinical trials based on therapeutic EVs registered; all of which are currently still recruiting (Fais et al., 2016; Lener et al., 2015). However only one official trial has been reported to date using ascites-derived exosomes for the treatment of colorectal cancer (Dai et al., 2008). Additionally, in a letter to the editor, the use of stem cell-derived EV administered under compassionate care to patients suffering from graft vs. host disease (GvHD) recorded no adverse effects (Kordelas et al., 2014). The first study was dated back to 2008 (Dai et al., 2008), while the second was published in 2014 (Kordelas et al., 2014). Since then, there is a modest increase in the number of clinical trials with five out of seven using biologically derived EVs while the remaining are plant based EVs. These trials are currently recruiting and are expected to commence in the near future.
Current methods for EV manufacturing are inadequate. Indeed, scalable manufacturing of clinical grade EVs to meet market demands will be a major challenge for this emerging sector for the foreseeable future (Figure 1). Given the unique attributes of EVs, considerable thought must be given to the preservation, formulation, and cold chain strategies in order to effectively translate exciting preclinical observations to clinical and commercial success.
FIGURE 1
Current Preservation Strategies for EVs
Conventional Methods for EVs Preservation
Since the commercial and clinical applications of EVs require standard criteria for long-term storage, cryopreservation methods have become a subject of growing interest. This section will describe the current understanding around EV preservation, challenges in maintaining EV stability, and their impact on long term storage and cold chain processes. Table 2 highlights the current preservation methods used in EV for therapeutics purposes.
Table 2
| Preservation method | Storage temperature | Storage solution | EV source | Isolation method | Reference |
|---|---|---|---|---|---|
| Conventional Freezing | -80°C | PBS | BMMSCs | Ultracentrifugation | Vallabhaneni et al., 2015 |
| -80° C | PBS | hAECs | Ultracentrifugation | Zhao et al., 2017 | |
| Ultrafiltration | |||||
| -80°C | PBS | iMSCs | Ultracentrifugation | Hu et al., 2015 | |
| Sucrose gradient | |||||
| Ultrafiltration | |||||
| -80°C | PBS | MSCs | Ultracentrifugation | Zhu et al., 2014; Pachler et al., 2017 | |
| -80°C | PBS | Cardiac fibroblasts and iPSCs | PEG precipitation | Hu et al., 2016 | |
| 4°C, -80°C | PBS | MSCs | Ultracentrifugation | Xin et al., 2012 | |
| -80°C | PBS | imDCs | Ultracentrifugation | Tian et al., 2014 | |
| Ultrafiltration | |||||
| -80°C | PBS | Mouse BMDCs | Ultrafiltration/diafiltration | Viaud et al., 2009 | |
| -80°C | PBS | Mouse BMDCs | Ultracentrifugation | Damo et al., 2015 | |
| Ultrafiltration | |||||
| -80°C | PBS | BMDCs | Ultracentrifugation | Naslund et al., 2013 | |
| -80°C | 0.9% normal saline | Dendritic cells | Ultracentrifugation on a D2O/sucrose cushion | Morse et al., 2005 | |
| -80°C | 0.9% NACl | MSCs | PEG precipitation | Ophelders et al., 2016 | |
| -20°C | PBS | Brain endothelial cells | Invitrogen® Total Exosome RNA and Protein Isolation Kit | Yang et al., 2015 | |
| -80°C | Total Exosome Isolation reagent | EPCs | Ultracentrifugation using Total Exosome Isolation reagent (GENESEED, China) | Ke et al., 2017 | |
| -80°C | Serum-free medium 199 + 25 mM HEPES | ADMSCs | Ultracentrifugation | Eirin et al., 2017 | |
| -80°C | Serum-free medium 199 + 25 mM HEPES | HUVECs | Ultracentrifugation | Zhang et al., 2014c | |
| -80°C | RPMI + 1% DMSO | HK-2 | Ultracentrifugation | Lindoso et al., 2014 | |
| +4°C, -80°C | PBS + 25 mM Trehalose | MIN6 cells | Ultracentrifugation | Bosch et al., 2016 | |
| -80°C | Serum-free Medium 199 | MSC | Ultracentrifugation | Bruno et al., 2009, 2012 | |
| Fibroblasts | |||||
| -80°C | Medium 199 | EPCs | Ultracentrifugation | Deregibus et al., 2012 | |
| Fibroblasts | |||||
| -80°C | Not disclosed | ESC-derived MSCs | Chromatography | Arslan et al., 2013 | |
| Ultrafiltration | |||||
| -80°C | Not disclosed | EPCs | Ultracentrifugation | Li et al., 2016 | |
| Filtration | |||||
| +4°C, +37°C, -20° C | Not disclosed | HEK293T, ECFC, MSCs | Ultracentrifugation | Sokolova et al., 2011 | |
| +60°C, +37°C, +4°C, -20°C, -80°C | Not disclosed | HEK293T | ExtraPEG reagent | Cheng et al., 2018 | |
| Freeze drying | +4°C, -20°C, -80°C | Plasmalyte A, Ringers, Plasmalyte A + Dextrose | Cardiosphere-derived cells | Ultrafiltration | Kreke et al., 2016 |
| Diafiltration | |||||
| -20°C | Laemmli Buffer | TM cells | Ultracentrifugation | Stamer et al., 2011 | |
| -80°C | PBS | LIM1215 cells | Ultracentrifugation | Lydic et al., 2015 | |
Current storage and preservation methods for EVs.
BMMSC, human bone marrow mesenchymal stem cells; hAECs, human amniotic epithelial cells; iMSCs, iPSCs, imDCs, BMDCs, ADMSCs: adipose tissue MSCs; HUVECs, human umbilical vein endothelial cells; HK-2, human kidney cell line; MIN6, murine pancreatic beta cell line; ESC-derived MSCs, human embryonic stem cell-derived MSCs; HEK293T, human embryonic kidney cells; ECFC, endothelial colony forming cells; TM, human trabecular mesh cells; LIM1215, human colorectal cancer cell line.
Cryopreservation
Cryopreservation with cryoprotectants (CPAs) is a widely accepted procedure to maintain protein stability and prevent osmotic damage (Elliott et al., 2017). Optimum EV dehydration can be achieved in the presence of CPAs by increasing viscosity, impacting the kinetics of ice nucleation, and allowing regulated extracellular ice growth during controlled cooling. However, excessively low concentrations of CPAs may result in chilling shock, which is defined as the damage caused by the freezing process. On the other hand, excessively high concentrations of CPAs can be toxic. Thus, a balance is needed to achieve optimal cryopreservation (Best, 2015).
CPAs refer to a diverse range of sugars, diols, and amino acids which work to stabilize biomolecules in a variety of ways depending on their molecular mass, examples of CPA application in molecular and cell biology is described on Table 3. Penetrating CPAs (pCPA) have low molecular weights (<100 Da) and work by permeating across the lipid bilayer membranes to stabilize the biomolecules (Figure 2). In contrast, non-penetrating CPAs (npCPA) remain external to the vesicle due to their high molecular mass (180–594 Da) and prevent cryodamage from hyperosmotic lysis (Jan et al., 2008; Motta et al., 2014). Notably, there is a growing body of evidence suggesting a combination of both pCPAs and npCPAs is more effective (Table 3) (Willison and Rowe, 1980; Ha et al., 2005).
Table 3
Cryoprotective agents (CPA) used in cryopreservation of biological materials.
PG, propylene glycol; DMSO, dimethyl sulphoxide; EG, ethylene glycol; PVP, Polyvinyl pyrrolidine.
FIGURE 2
A wide range of substances have been used as stabilizers in conventional cryopreservation methods. Specifically, disaccharides are a safe choice for EV-based therapeutics. Trehalose, a natural non-reducing disaccharide, is an FDA-approved CPA for a wide range of proteins and cell products (Eroglu et al., 2000; Buchanan et al., 2004; Motta et al., 2014; Bosch et al., 2016). Following reports showing the importance of adding pCPAs and npCPAs, trehalose was suggested as an ideal candidate to preserve hematopoietic and embryonic stem cells as well as other progenitor cells for therapeutic applications (Buchanan et al., 2004, 2005). Trehalose prevented aggregation by avoiding internal ice formation in biological particles such as liposomes and EVs (Bosch et al., 2016). The addition of trehalose also increased the colloidal stability of EVs (Hood et al., 2014).
Lyophilisation/Freeze Drying
Freeze-drying or lyophilisation is currently thought to be the most reliable method to preserve thermolabile materials such as proteins, peptides, vaccines, colloidal carriers, EVs and viruses (Khairnar et al., 2013; Hansen et al., 2015). The first step in lyophilisation involves the freezing or solidification of the EVs, when cooling rate correlates inversely with the size of the ice crystal. The crystallized material is then sublimated directly into water vapor. Freezing and dehydration stresses generated during lyophilisation may result in destructive effects on the structure of biomolecules within the EV, and thus necessitates the use of CPAs in the formulation to protect the EVs and their cargo (Wu et al., 2015a).
The stability of lyophilised EVs significantly extends their shelf life, lowers storage demands, and costs owing to a simplified cold chain. For example, the best storage temperature reported for lyophilised EVs isolated from cardiospheres was 4°C (Kreke et al., 2016). The most common stabilizers used in lyophilisation are disaccharides such as glucose, lactose, sucrose and trehalose, which work by replacing the hydration sphere around the EVs through a hydrogen bonding interaction with phospholipid head groups to form an amorphous sugar glass. The glassy state produced in the presence of disaccharides prevent fusion of products or protein destabilization (Jain and Roy, 2009).
Trehalose has been suggested as the most effective disaccharide to preserve EVs during lyophilisation (Chen et al., 2010; Bosch et al., 2016). This promising technique is an FDA-approved method for a range of proteins, liposomes and nanoparticles that enables their use in the pharmaceutical industry (Van Backstal et al., 2017).
Spray Drying
Spray drying is a common method for producing a wide variety of therapeutic agents including vaccines, peptides and proteins for inhaled delivery (Broadhead et al., 1992; Chan et al., 1997; Salama et al., 2009). This single-step process substantially reduces the need for expensive equipment and lengthier multi-step processes. Spray drying is scalable and operators are able to tune the particle size of the final product by controlling the spray droplet size and solute concentration, thereby providing a major point of difference from lyophilisation where the particle size reduction can occur only through mechanical milling (Costantino et al., 2000).
Spray drying involves an initial step of atomising the solution containing EVs. These droplets are rapidly converted into a dry powder using heated gas (Lee, 2002). Spray drying is a continuous process and can be both automated and instrumented for enhanced process control. The reduction in moisture content of particles formed during the spray drying process generally increases the stability of the biopharmaceuticals in these particles: the residual moisture acts as a plasticiser to reduce glass transition temperature of the particle solid state, and its presence may also enhance chemical instability. Critical process parameters such as the rate at which EV solution is being fed into the system, the atomisation pressure and outlet temperature, can all affect the stability of the EVs and their cargo. These critical process parameters must therefore be identified and maintained within a narrow window (Masters, 1972). Behfar (2016) patented a technique to encapsulate the platelet rich solution EVs as a candidate for wound healing (US20160324794A1). However, further investigation is needed to apply this technique more broadly to the manufacturing and storage of EV-based therapeutics.
Challenges Associated With EVs Preservation
In order for EV-based therapeutics to be manufactured and used reproducibly, storage conditions must have minimal impact on EV structural integrity. The following section will discuss parameters known to affect EV composition, biological potency and structural integrity.
Storage Temperature and Shelf Life
There have been a number of studies conducted to determine the most favorable storage conditions for EVs. Focusing on EVs with intended therapeutic applications, EVs from human embryonic kidney (HEK) 293T cells, endothelial colony forming cells (ECFCs) and MSCs report -20°C as the highest temperature in which EVs are stable (Sokolova et al., 2011). These results are in line with the standard preservation temperature reported by ISEV for EVs storage. In contrast, another study has reported that -70°C is the best long-term storage temperature for EVs isolated using the Exo-Quick kit (System Biosciences, Palo Alto, CA, United States) (Lee et al., 2016).
Freeze Thaw Stress
While freeze-thaw cycles do not affect the stability of EVs isolated from plasma and exosomal miRNA and different cell types like HEK293T, ECFCs and MSCs (Sokolova et al., 2011; Lv et al., 2013; Ge et al., 2014), other studies show that EVs can be structurally susceptible due to the exposure of vulnerable phosphatidylserine to repeated freeze-thaw cycles (Wu et al., 2015b; Maroto et al., 2017). This is an area that must be deconvoluted as EV-based therapeutics are being developed, in order to establish a clear product stability profile as required by regulatory bodies.
A Bioengineering Approach to Manufacturing and Enhancing EV Stability
Overcoming Aggregation in EV Preparations
A preparation of EVs can be considered as a colloid – a solution in which microscopically dispersed particles are suspended (Hood et al., 2014). From this perspective, there are several known phenomena that can be applied to EVs, providing a rationale underlying the basis of possible approaches that can be used to increase the stability and quality of stored EVs. One of the major challenges in EV storage, particle aggregation, occurs when inter-particle attraction is greater than repulsion. Such interactions are governed by factors such as surface charge, hydrophobicity and fluidity (Takeuchi et al., 2000). Strategies to prevent EV aggregation must therefore modify these factors to increase inter-particle repulsion and stabilize the colloidal solution.
Although EV biology is a relatively new field, EVs share many overarching structural features with liposomes – lipid bilayered vesicles that have been well-studied due to their utility as drug delivery vehicles. Looking toward liposome studies, the use of hydrophilic polymers as steric stabilizers may be a good strategy for preservation of a colloidal system. When using polymers, it is thought that the hydrophilic chains extend from the liposomes out into the solution thereby stabilizing the system so that the individual particles remain well-dispersed (Figure 3).
FIGURE 3
The most common polymer used in liposome stabilization is PEG (polyethylene glycol). Advantages of PEG include the fact that it is non-fouling, well-tolerated by the body, can be obtained in a wide range of molecular weights and end-group chemistries and that it is FDA approved for a range of medical applications (Hasan, 2017). There are many examples in which liposomes have been PEGylated, i.e., the PEG chains are incorporated within the lipid bilayer during synthesis (e.g., PEGlyated liposomes to incorporate itraconazole, antifungal agent, as well as dopamine-loaded PEGylated immunoliposomes; Kang et al., 2016; Dzieciuch-Rojek et al., 2017). Although effective, such a strategy is unsuitable for EV stabilization. Coating the particles in polymer can have a similar effect and would be a much more suitable strategy for EV preservation, allowing EVs to be stabilized by the simple addition of polymer to the isolated preparation. Other polymers that have been used include the synthetic polymer PVA (polyvinylalcohol), and the naturally derived polysaccharides OPP (O-palmitoylpullulan), chitosan, and hyaluronic acid (Sehgal and Rogers, 1995; Takeuchi et al., 2000; Manconi et al., 2017). Specific stabilization of EVs has thus far been limited to the use of trehalose. Addition of trehalose to solutions of EVs was proven to enhance colloidal stability during electroporation, for the modification of EV cargo (Hood et al., 2014). Addition of 25 mM trehalose to EVs derived from pancreatic beta cells was observed to narrow the particle size distribution (i.e., increase the stability) and improve the particle yield (Bosch et al., 2016), presumably by also reducing loss of EVs through interactions with the walls of the storage vessel.
Biomaterial Scaffolds for EV Stability and Delivery
The matrix of tissues in the body hosts a population of vesicles, often termed matrix bound vesicles (MBVs) (Shapiro et al., 2015; Huleihel et al., 2016). In a similar manner to the protection of growth factors by sequestration and release from the extracellular matrix (ECM), the binding of these vesicles has a vital role in enhancing their stability and biological availability. Although, there is still debate as to whether MBVs possess all of the characteristics required to be defined as an EV, there is also evidence that EVs can bind to ECM components; for example, a study by Narayanan et al. showed binding of MSC-derived EVs to bind to both fibronectin and collagen type I in the ECM (Narayanan et al., 2016). Such interactions between EVs and the ECM are likely mediated by adhesion receptors, known to be present on the exosomal membrane, including integrins, tetraspanins, and ICAM-1 (Escola et al., 1998; Thery et al., 1999, 2001; Rana and Zoller, 2013).
In the case of MBVs, interaction with the matrix has proven to enhance their stability. MBVs can survive chemical, enzymatic and detergent-based treatments and subsequently induce changes in cellular behavior (Huleihel et al., 2016). These intriguing findings indicate that incorporation of EVs with ECM or biomaterial components may be a powerful tool to both enhance EV stability and provide a controlled spatiotemporal release within the body. This premise is supported by a few early studies in which EVs have been incorporated into biomaterial constructs for delivery. For example, Zhang et al. (2016) stabilized MSC-derived EVs by incorporation into porous tricalcium phosphate (β-TCP) scaffolds. In doing so they demonstrated that EVs could be released over several days and further that the function of these EVs in promoting bone repair was retained. In another study, Shi et al. combined MSC-EVs with a hydrogel synthesized from chitosan and silk, showing that EVs incorporated into the biomaterial could be released over time and retained their function to improve wound healing (Shi et al., 2017). Although, in its infancy, these studies uniting EV biology and bioengineering provide an exciting glimpse into future applications of biomaterials to preserve and deliver EVs for therapeutic application.
Future Directions
Given that EVs largely retain the properties of their cells of origin, it is unsurprising that cell therapy companies have jumped on this particular bandwagon in order to maximize the proprietary cell lines. For example, Capricor Therapeutics (Beverly Hills, CA, United States) are investigating the clinical potential of CAP-2003, which refer to the EVs produced by their proprietary cardiosphere-derived cells. Capricor has made efforts to evaluate the regenerative potential of these cardiosphere-derived EVs on diseases involving inflammation and fibrosis (Ibrahim et al., 2014). Similarly, cell therapy company specializing in neurological disease, ReNeuron, has sought to do the same with EVs from their proprietary CTX neural cell line, which are currently in Phase IIb clinical trials for US-based patients living with post-stroke disabilities. It is likely that we will need an emergence of EV-based therapeutics from other cell therapy companies as the proverbial penny drops – there is immense value in what was essentially considered a waste product of cell manufacturing.
Regardless of whether EVs will be used for the purposes of regenerative medicine, cancer vaccination, veterinary or agriculture, there is an obvious need to develop methods to reliably store, transport and apply the EVs. Of these considerations, storage of the EVs is perhaps the most critical aspect of the supply chain. The stability of the EVs in their storage medium necessarily dictates the rigidity of the cold chain and will have direct impact on the cost of goods. Investment into technologies that refine the stability of EVs will likely afford significant cost savings downstream. The storage medium will also impact the final formulation of the EV therapeutic as challenges around solubility of injectables and particle size of aerosols must be considered. These factors will have knock-on effects on biodistribution and therapeutic efficacy. As such, rigorous preclinical testing should be designed with this in mind, in order to expedite product development and facilitate regulatory approval.
Conclusion
The FDA approval of chimeric antigen receptor T cells (CAR-T), Kymriah (Novartis) for refractory B-cell precursor acute lymphoblastic leukemia in August 2017, heralded the dawn of a new age for cell therapies. There are, however, broader implications for these approved cell therapies. Chief amongst these is the growing acceptance of cellular therapies and regenerative medicine in mainstream clinical care. However, the relative high cost of goods remains prohibitive for cellular therapies. Challenges in scalable manufacturing, maintenance of a master cell bank, complex cold chain logistics and ambiguity around product release criteria, have led to lengthy delays in realizing the potential of cellular therapies. While regulatory hurdles for this new class of biologics remain a challenge to be met, it is likely that the relative stability of EVs will see a significantly expedited path to regulatory approval. Furthermore, as critical questions around scalable manufacturing and long-term preservation are answered, EV-based therapeutics may offer a more affordable form of regenerative medicine, thereby increasing market penetration and patient access. In essence, the development of novel preservation protocols tailored for EVs are likely to fast forward the manufacturing process to establish EVs as commercially viable therapeutics.
Statements
Author contributions
GK, MB, JT, DM, JF, and RL contributed to the writing and editing of this manuscript. GK and JT prepared the figures. GK and MB prepared the tables.
Funding
The work was supported by Interdisciplinary Research Seed Funding Scheme from Monash University (awarded to JF and RL). This work is supported by the Victorian Government’s Operational Infrastructure Support Program.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Footnotes
References
1
AbdelwahedW.DegobertG.FessiH. (2006a). A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): formulation and process optimization.Int. J. Pharm.309178–188. 10.1016/j.ijpharm.2005.10.003
2
AbdelwahedW.DegobertG.FessiH. (2006b). Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage.Eur. J. Pharm. Biopharm.6387–94. 10.1016/j.ejpb.2006.01.015
3
AdmyreC.BohleB.JohanssonS. M.Focke-TejklM.ValentaR.ScheyniusA.et al (2007). B cell-derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce TH2-like cytokines.J. Allergy Clin. Immunol.1201418–1424. 10.1016/j.jaci.2007.06.040
4
AlihosseiniF.GhaffariS.DabirsiaghiA. R.HaghighatS. (2015). Freeze-drying of ampicillin solid lipid nanoparticles using mannitol as cryoprotectant.Braz. J. Pharm. Sci.51797–802. 10.1590/S1984-82502015000400005
5
AlmalikA.AlradwanI.KalamM. A.AlshamsanA. (2017). Effect of cryoprotection on particle size stability and preservation of chitosan nanoparticles with and without hyaluronate or alginate coating.Saudi Pharm. J.25861–867. 10.1016/j.jsps.2016.12.008
6
AmarnathS.FoleyJ. E.FarthingD. E.GressR. E.LaurenceA.EckhausM. A.et al (2015). Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human th1 cells in vivo.Stem Cells331200–1212. 10.1002/stem.1934
7
AndersonJ. D.JohanssonH. J.GrahamC. S.VesterlundM.PhamM. T.BramlettC. S.et al (2016). Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappaB signaling.Stem Cells34601–613. 10.1002/stem.2298
8
AnnE. (2005). Available at: Intact cell fzw /.1
9
ArslanF.LaiR. C.SmeetsM. B.AkeroydL.ChooA.AguorE. N. E.et al (2013). Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury.Stem Cell Res.10301–312. 10.1016/j.scr.2013.01.002
10
BadowskiM.MuiseA.HarrisD. T. (2014). Mixed effects of long-term frozen storage on cord tissue stem cells.Cytotherapy161313–1321. 10.1016/j.jcyt.2014.05.020
11
BatistaB. S.EngW. S.PilobelloK. T.Hendricks-MunozK. D.MahalL. K. (2011). Identification of a conserved glycan signature for microvesicles.J. Proteome Res.104624–4633. 10.1021/pr200434y
12
BeattieG. M.CroweJ. H.LopezA. D.CirulliV.RicordiC.HayekA. (1997). Trehalose: a cryoprotectant that enhances recovery and preserves function of human pancreatic islets after long-term storage.Diabetes Metab. Res. Rev.46519–523. 10.2337/diab.46.3.519
13
BehfarA. (2016). Exosome delivery technololgy. Patent No: US20160324794
14
BestB. P. (2015). Cryoprotectant toxicity: facts, issues, and questions.Rejuvenation Res.18422–436. 10.1089/rej.2014.1656
15
BissoyiA.PramanikK. (2013) Effects of non-toxic cryoprotective agents on the viability of cord blood derived MNCs. Cryo. Letters34453–465.
16
BoschS.De BeaurepaireL.AllardM.MosserM.HeichetteC.ChrétienD.et al (2016). Trehalose prevents aggregation of exosomes and cryodamage.Sci. Rep.6:36162. 10.1038/srep36162
17
BozzoT. (1999). Blood component recalls.Transfusion39439–441. 10.1046/j.1537-2995.1999.39050439.x
18
BroadheadJ.Edmond RouanS. K.RhodesC. T. (1992). The spray drying of pharmaceuticals.Drug Dev. Ind. Pharm.181169–1206. 10.3109/03639049209046327
19
BruderS. P.JaiswalN.HaynesworthS. E. (1997). Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation.J. Cell. Biochem.64278–294. 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F
20
BrunoS.GrangeC.CollinoF.DeregibusM. C.CantaluppiV.BianconeL.et al (2012). Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury.PLoS One7:e33115. 10.1371/journal.pone.0033115
21
BrunoS.GrangeC.DeregibusM. C.CalogeroR. A.SaviozziS.CollinoF.et al (2009). Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.J. Am. Soc. Nephrol.201053–1067. 10.1681/ASN.2008070798
22
BuN.WuH.-Q.ZhangG.-L.ZhanS.-Q.ZhangR.FanQ.-Y.et al (2015). Immature dendritic cell exosomes suppress experimental autoimmune myasthenia gravis.J. Neuroimmunol.28571–75. 10.1016/j.jneuroim.2015.04.009
23
BuchananS. S.GrossS. A.AckerJ. P.TonerM.CarpenterJ. F.PyattD. W. (2004). Cryopreservation of stem cells using trehalose: evaluation of the method using a human hematopoietic cell line.Stem Cells Dev.13295–305. 10.1089/154732804323099226
24
BuchananS. S.MenzeM. A.HandS. C.PyattD. W.CarpenterJ. F. (2005). Cryopreservation of human hematopoietic stem and progenitor cells loaded with trehalose: transient permeabilization via the adenosine triphosphate-dependent P2Z receptor channel.Cell Preserv. Technol.3212–222. 10.1089/cpt.2005.3.212
25
CantaluppiV.BianconeL.FiglioliniF.BeltramoS.MedicaD.DeregibusM. C.et al (2012). Microvesicles derived from endothelial progenitor cells enhance neoangiogenesis of human pancreatic islets.Cell Transplant.211305–1320. 10.3727/096368911X627534
26
CardosoL. M. D. F.PintoM. A.Henriques PonsA.AlvesL. A. (2017). Cryopreservation of rat hepatocytes with disaccharides for cell therapy.Cryobiology7815–21. 10.1016/j.cryobiol.2017.07.010
27
Carrasco-RamírezP.GreeningD. W.AndrésG.GopalS. K.Martín-VillarE.RenartJ.et al (2016). Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation.Oncotarget716070–16089. 10.18632/oncotarget.7445
28
Casado-DíazA.Santiago-MoraR.JiménezR.Caballero-VillarrasoJ.HerreraC.TorresA.et al (2008). Cryopreserved human bone marrow mononuclear cells as a source of mesenchymal stromal cells: application in osteoporosis research.Cytotherapy10460–468. 10.1080/14653240802192644
29
ChacónM.MolpeceresJ.BergesL.GuzmánM.AberturasM. R. (1999). Stability and freeze-drying of cyclosporine loaded poly(D,L-lactide-glycolide) carriers.Eur. J. Pharm. Sci.899–107. 10.1016/S0928-0987(98)00066-9
30
ChanH. K.ClarkA.GondaI.MumenthalerM.HsuC. (1997). Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery.Pharm. Res.14431–437. 10.1023/A:1012035113276
31
ChangY.-P.HongH.-P.LeeY.-H.LiuI.-H. (2015). The canine epiphyseal-derived mesenchymal stem cells are comparable to bone marrow derived-mesenchymal stem cells.J. Vet. Med. Sci.77273–280. 10.1292/jvms.14-0265
32
ChaseL. C. G.RaoM. S. G.VemuriM. S. (2011). Mesenchymal stem cell assays and applications.Methods Mol. Biol.6983–8. 10.1007/978-1-60761-999-4
33
ChatzistamatiouT. K.PapassavasA. C.MichalopoulosE.GamaloutsosC.MallisP.GontikaI.et al (2014). Optimizing isolation culture and freezing methods to preserve Wharton’s jelly’s mesenchymal stem cell (MSC) properties: an MSC banking protocol validation for the Hellenic Cord Blood Bank.Transfusion543108–3120. 10.1111/trf.12743
34
ChenC.HanD.CaiC.TangX. (2010). An overview of liposome lyophilization and its future potential.J. Control. Release142299–311. 10.1016/j.jconrel.2009.10.024
35
ChenG.YueA.RuanZ.YinY.WangR.RenY.et al (2016). Comparison of the effects of different cryoprotectants on stem cells from umbilical cord blood.Stem Cells Int.2016:1396783. 10.1155/2016/1396783
36
ChengY.ZengQ.HanQ.XiaW. (2018). Effect of pH, temperature and freezing-thawing on quantity changes and cellular uptake of exosomes.Protein Cell71–5. 10.1007/s13238-018-0529-4
37
ChoudheryM. S.BadowskiM.MuiseA.PierceJ.HarrisD. T. (2014). Cryopreservation of whole adipose tissue for future use in regenerative medicine.J. Surg. Res.18724–35. 10.1016/j.jss.2013.09.027
38
ColinoJ.SnapperC. M. (2006). Exosomes from bone marrow dendritic cells pulsed with diphtheria toxoid preferentially induce type 1 antigen-specific IgG responses in naive recipients in the absence of free antigen.J. Immunol.1773757–3762. 10.4049/jimmunol.177.6.3757
39
CostantinoH. R.FirouzabadianL.HogelandK.WuC.BeganskiC.CarrasquilloK. G.et al (2000). Protein spray-freeze drying. Effect of atomization conditions on particle size and stability.Pharm. Res.171374–1383. 10.1023/A:1007570030368
40
CroweJ. H.CroweL. M.CarpenterJ. F.Aurell WistromC. (1987). Stabilization of dry phospholipid bilayers and proteins by sugars.Biochem. J.2421–10. 10.1042/bj2420001
41
CruzF. F.BorgZ. D.GoodwinM.SokocevicD.WagnerD. E.CoffeyA.et al (2015). Systemic administration of human bone marrow-derived mesenchymal stromal cell extracellular vesicles ameliorates aspergillus hyphal extract-induced allergic airway inflammation in immunocompetent mice.Stem Cells Transl. Med.41302–1316. 10.5966/sctm.2014-0280
42
CuiZ.HsuC. H.MumperR. J. (2003). Physical characterization and macrophage cell uptake of mannan-coated nanoparticles.Drug Dev. Ind. Pharm.29689–700. 10.1081/DDC-120021318
43
DaiS.WeiD.WuZ.ZhouX.WeiX.HuangH.et al (2008). Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer.Mol. Ther.16782–790. 10.1038/mt.2008.1
44
DamjanovicV.ThomasD. (1974). The use of polyvinylpyrrolidone as a cryoprotectant in the freezing of human lymphocytes.Cryobiology11312–316. 10.1016/0011-2240(74)90007-8
45
DamoM.WilsonD. S.SimeoniE.HubbellJ. A. (2015). TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma.Sci. Rep.5:17622. 10.1038/srep17622
46
DariolliR.BassanezeV.NakamutaJ. S.OmaeS. V.CamposL. C. G.KriegerJ. E. (2013). Porcine adipose tissue-derived mesenchymal stem cells retain their proliferative characteristics, senescence, karyotype and plasticity after long-term cryopreservation.PLoS One8:e67939. 10.1371/journal.pone.0067939
47
DateP. V.SamadA.DevarajanP. V. (2010). Freeze thaw: a simple approach for prediction of optimal cryoprotectant for freeze drying.AAPS PharmSciTech11304–313. 10.1208/s12249-010-9382-3
48
De Lara JanzF.De Aguiar DebesA.De Cássia CavaglieriR.DuarteS. A.RomãoC. M.MorónA. F.et al (2012). Evaluation of distinct freezing methods and cryoprotectants for human amniotic fluid stem cells cryopreservation.J. Biomed. Biotechnol.2012:649353. 10.1155/2012/649353
49
Del FattoreA.LucianoR.PascucciL.GoffredoB. M.GiordaE.ScapaticciM.et al (2015). Immunoregulatory effects of mesenchymal stem cell-derived extracellular vesicles on T lymphocytes.Cell Transplant.242615–2627. 10.3727/096368915X687543
50
DeregibusM. C.CantaluppiV.CalogeroR.Lo IaconoM.TettaC.BrunoS.et al (2012). Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA.Blood1102440–2448. 10.1182/blood-2007-03-078709
51
DingG.WangW.LiuY.AnY.ZhangC.ShiS.et al (2010). Effect of cryopreservation on biological and immunological properties of stem cells from apical papilla.J. Cell. Physiol.223415–422. 10.1002/jcp.22050
52
DulugiacM.MoldovanL.ZarnescuO. (2015). Comparative studies of mesenchymal stem cells derived from different cord tissue compartments - The influence of cryopreservation and growth media.Placenta361192–1203. 10.1016/j.placenta.2015.08.011
53
Dzieciuch-RojekM.PoojariC.BednarJ.BunkerA.KozikB.NowakowskaM.et al (2017). Effects of membrane PEGylation on entry and location of antifungal drug itraconazole and their pharmacological implications.Mol. Pharm.141057–1070. 10.1021/acs.molpharmaceut.6b00969
54
EdamuraK.NakanoR.FujimotoK.TeshimaK.AsanoK.TanakaS. (2014). Effects of cryopreservation on the cell viability, proliferative capacity and neuronal differentiation potential of canine bone marrow stromal cells.J. Vet. Med. Sci.76573–577. 10.1292/jvms.13-0296
55
EirinA.ZhuX.-Y.PuranikA. S.TangH.McGurrenK. A.van WijnenA. J.et al (2017). Mesenchymal stem cell-derived extracellular vesicles attenuate kidney inflammation.Kidney Int.92114–124. 10.1016/j.kint.2016.12.023
56
El AssalR.GuvenS.GurkanU. A.GozenI.ShafieeH.DalbeylerS.et al (2014). Bio-inspired cryo-ink preserves red blood cell phenotype and function during nanoliter vitrification.Adv. Mater.265815–5822. 10.1002/adma.201400941
57
ElliottG. D.WangS.FullerB. J. (2017). Cryobiology Cryoprotectants : a review of the actions and applications of cryoprotective solutes that modulate cell recovery from ultra-low temperatures.Cryobiology7674–91. 10.1016/j.cryobiol.2017.04.004
58
El-NesrO. H.YahiyaS. A.El-GazayerlyO. N. (2010). Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes.Saudi Pharm. J.18217–224. 10.1016/j.jsps.2010.07.003
59
ErogluA.RussoM. J.BieganskiR.FowlerA.CheleyS.BayleyH.et al (2000). Intracellular trehalose improves the survival of cryopreserved mammalian cells.Nat. Biotechnol.18163–167. 10.1038/72608
60
ErogluA.TonerM.TothT. L. (2002). Beneficial effect of microinjected trehalose on the cryosurvival of human oocytes.Fertil. Steril.77152–158. 10.1016/S0015-0282(01)02959-4
61
EscolaJ. M.KleijmeerM. J.StoorvogelW.GriffithJ. M.YoshieO.GeuzeH. J. (1998). Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes.J. Biol. Chem.27320121–20127. 10.1074/jbc.273.32.20121
62
FaisS.O’DriscollL.BorrasF. E.BuzasE.CamussiG.CappelloF.et al (2016). Evidence-based clinical use of nanoscale extracellular vesicles in nanomedicine.ACS Nano103886–3899. 10.1021/acsnano.5b08015
63
FavaroE.CarpanettoA.CaorsiC.GiovarelliM.AngeliniC.Cavallo-PerinP.et al (2016). Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients.Diabetologia59325–333. 10.1007/s00125-015-3808-0
64
FavaroE.CarpanettoA.LamorteS.FuscoA.CaorsiC.DeregibusM. C.et al (2014). Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes.Diabetologia571664–1673. 10.1007/s00125-014-3262-4
65
FengY.HuangW.WaniM.YuX.AshrafM. (2014). Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22.PLoS One9:e88685. 10.1371/journal.pone.0088685
66
FonteP.SoaresS.CostaA.AndradeJ. C.SeabraV.ReisS.et al (2012). Effect of cryoprotectants on the porosity and stability of insulin-loaded PLGA nanoparticles after freeze-drying.Biomatter2329–339. 10.4161/biom.23246
67
FreimarkD.SehlC.WeberC.HudelK.CzermakP.HofmannN.et al (2011). Systematic parameter optimization of a Me2SO- and serum-free cryopreservation protocol for human mesenchymal stem cells.Cryobiology6367–75. 10.1016/j.cryobiol.2011.05.002
68
GalaR. P.KhanI.ElhissiA. M. A.AlhnanM. A. (2015). A comprehensive production method of self-cryoprotected nano-liposome powders.Int. J. Pharm.486153–158. 10.1016/j.ijpharm.2015.03.038
69
GeQ.ZhouY.LuJ.BaiY.XieX.LuZ. (2014). MiRNA in plasma exosome is stable under different storage conditions.Molecules191568–1575. 10.3390/molecules19021568
70
GnecchiM.DanieliP.MalpassoG.CiuffredaM. C. (2016). “Paracrine mechanisms of mesenchymal stem cells in tissue repair,” inMesenchymal Stem Cells: Methods and Protocols, ed.GnecchiM. (New York, NY: Springer), 123–146. 10.1007/978-1-4939-3584-0_7
71
HaS. Y.JeeB. C.SuhC. S.KimH. S.OhS. K.KimS. H.et al (2005). Cryopreservation of human embryonic stem cells without the use of a programmable freezer.Hum. Reprod.201779–1785. 10.1093/humrep/deh854
72
HansenL. J. J.DaoussiR.VervaetC.RemonJ. -P.De BeerT. R. M. (2015). Freeze-drying of live virus vaccines: a review.Vaccine335507–5519. 10.1016/j.vaccine.2015.08.085
73
HarriganP. R.MaddenT. D.CullisP. R. (1990). Protection of liposomes during dehydration or freezing.Chem. Phys. Lipids52139–149. 10.1016/0009-3084(90)90157-M
74
HasanA. (2017). TissueEngineering for Artificial Organs. Available at: https://onlinelibrary.wiley.com/doi/book/10.1002/9783527689934
75
HauZ. Z.LiB. G.LiuZ. J.SunD. W. (2003). Freeze-drying of liposomes with cryoprotectants and its effect on retention rate of encapsulated ftorafur and vitamin A.Dry. Technol.211491–1505. 10.1081/DRT-120024489
76
HeinrichU.GarbeB.TronnierH. (2007). In vivo assessment of ectoin: a randomized, vehicle-controlled clinical trial.Skin Pharmacol. Physiol.20211–218. 10.1159/000103204
77
HendriksJ.RiesleJ.van BlitterswijkC. A. (2010). Co-culture in cartilage tissue engineering.J. Tissue Eng. Regen. Med.4524–531. 10.1002/term
78
HergenreiderE.HeydtS.TreguerK.BoettgerT.HorrevoetsA. J. G.ZeiherA. M.et al (2012). Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs.Nat. Cell Biol.14249–256. 10.1038/ncb2441
79
HewsonC.CapraroD.BurdachJ.WhitakerN.MorrisK. V. (2016). Extracellular vesicle associated long non-coding RNAs functionally enhance cell viability.Noncoding RNA Res.13–11. 10.1016/j.ncrna.2016.06.001
80
HoodJ. L.ScottM. J.WicklineS. A. (2014). Maximizing exosome colloidal stability following electroporation.Anal. Biochem.44841–49. 10.1016/j.ab.2013.12.001
81
HuG. W.LiQ.NiuX.HuB.LiuJ.ZhouS. M.et al (2015). Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice.Stem Cell Res. Ther.61–15. 10.1186/scrt546
82
HuL.WangJ.ZhouX.XiongZ.ZhaoJ.YuR.et al (2016). Exosomes derived from human adipose mensenchymal stem cells accelerates cutaneous wound healing via optimizing the characteristics of fibroblasts.Sci. Rep.6:32993. 10.1038/srep32993
83
HuY.RaoS.-S.WangZ.-X.CaoJ.TanY.-J.LuoJ.et al (2018). Exosomes from human umbilical cord blood accelerate cutaneous wound healing through miR-21-3p-mediated promotion of angiogenesis and fibroblast function.Theranostics8169–184. 10.7150/thno.21234
84
HuangH.ChoiJ. K.RaoW.ZhaoS.AgarwalP.ZhaoG.et al (2015). Alginate hydrogel microencapsulation inhibits devitrification and enables large-volume low-CPA cell vitrification.Adv. Funct. Mater.256839–6850. 10.1002/adfm.201503047
85
HuleihelL.HusseyG. S.NaranjoJ. D.ZhangL.DzikiJ. L.TurnerN. J.et al (2016). Matrix-bound nanovesicles within ECM bioscaffolds.Sci. Adv.2:e1600502. 10.1126/sciadv.1600502
86
IbrahimA. G.ChengK.MarbanE. (2014). Exosomes as critical agents of cardiac regeneration triggered by cell therapy.Stem Cell Rep.2606–619. 10.1016/j.stemcr.2014.04.006
87
IglesiasD. M.El-KaresR.TarantaA.BellomoF.EmmaF.BesouwM.et al (2012). Stem cell microvesicles transfer cystinosin to human cystinotic cells and reduce cystine accumulation in vitro.PLoS One7:e42840. 10.1371/journal.pone.0042840
88
JainN. K.RoyI. (2009). Effect of trehalose on protein structure.Protein Sci.1824–36. 10.1002/pro.3
89
JanD. B.Van BlitterswijkC.ThomsenP.HubbellJ.CanceddaR.de BruijnJ. D.LindahlA.et al (2008). Tissue Engineering.Amsterdam: Elsevier, 369.
90
JongA. Y.WuC. H.LiJ.SunJ.FabbriM.WayneA. S.et al (2017). Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells.J. Extracell. Vesicles6:1294368. 10.1080/20013078.2017.1294368
91
KalraH.DrummenG. P. C.MathivananS. (2016). Focus on extracellular vesicles: introducing the next small big thing.Int. J. Mol. Sci.17:170. 10.3390/ijms17020170
92
KangY.-S.JungH.-J.OhJ.-S.SongD.-Y. (2016). Use of PEGylated immunoliposomes to deliver dopamine across the blood-brain barrier in a rat model of parkinson’s disease.CNS Neurosci. Ther.22817–823. 10.1111/cns.12580
93
KatenzE.VondranF. W.SchwartlanderR.PlessG.GongX.ChengX.NeuhausP.et al (2007). Cryopreservation of primary human hepatocytes: the benefit of trehalose as an additional cryoprotective agent.Liver Transplant.13465–466. 10.1002/lt
94
KatsudaT.TsuchiyaR.KosakaN.YoshiokaY.TakagakiK.OkiK.et al (2013). Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.Sci. Rep.3:1197. 10.1038/srep01197
95
KavianiM.EzzatabadipourM.Nematollahi-MahaniS. N.SalehinejadP.MohammadiM.KalantarS. M.et al (2014). Evaluation of gametogenic potential of vitrified human umbilical cord Wharton’s jelly-derived mesenchymal cells.Cytotherapy16203–212. 10.1016/j.jcyt.2013.10.015
96
KeX.YangD.LiangJ.WangX.WuS.WangX.et al (2017). Human endothelial progenitor cell-derived exosomes increase proliferation and angiogenesis in cardiac fibroblasts by promoting the mesenchymal–endothelial transition and reducing high mobility group box 1 protein B1 expression.DNA Cell Biol.361018–1028. 10.1089/dna.2017.3836
97
KeerthikumarS.ChisangaD.AriyaratneD.Al SaffarH.AnandS.ZhaoK.et al (2016). ExoCarta: a web-based compendium of exosomal cargo.J. Mol. Biol.428688–692. 10.1016/j.jmb.2015.09.019
98
KesenciK.MottaA.FambriL. (2001). Poly(ε-caprolactone-co-D, L-lactide)/silk fibroin composite materials: preparation and characterization.J. Biomater. Sci. Polym. Ed.12337–351. 10.1016/S0939
99
KhairnarS.KiniR.HarwalkerM.SlaunkheK.ChaudhariS. (2013). A review on freeze drying process and pharmaceuticals.Int. J. Res. Pharm. Sci.476–94.
100
KhatuaA. K.TaylorH. E.HildrethJ. E. K.PopikW. (2009). Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells.J. Virol.83512–521. 10.1128/JVI.01658-08
101
KimC.-G.YongH.LeeG.ChoJ. (2008). Effect of the polyvinylpyrrolidone concentration of cryoprotectant on mouse embryo development and production of pups: 7.5% of PVP is beneficial for in vitro and in vivo development of frozen-thawed mouse embryos.J. Reprod. Dev.54250–253. 10.1262/jrd.19185
102
KordelasL.RebmannV.LudwigA.-K.RadtkeS.RuesingJ.DoeppnerT. R.et al (2014). MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease.Leukemia28970–973. 10.1038/leu.2014.41
103
KotobukiN.HiroseM.MachidaH.KatouY.MurakiK.TakakuraY.et al (2005). Viability and osteogenic potential of cryopreserved human bone marrow-derived mesenchymal cells.Tissue Eng.11663–673. 10.1089/ten.2005.11.663
104
KrekeM.SmithR.HanscomeP.PeckK.IbrahimA. (2016). Processes for producing stable exosome formulations. U.S. Patent No 14/958,804.
105
KumarV.QinJ.JiangY.DuncanR. G.BrighamB.FishmanS.et al (2014). Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy.Mol. Ther. Nucleic Acids3:e210. 10.1038/mtna.2014.61
106
KusumaG. D.CarthewJ.LimR.FrithJ. E. (2017). Effect of the microenvironment on mesenchymal stem cells paracrine signalling: opportunities to engineer the therapeutic effect.Stem Cells Dev.26617–631. 10.1089/scd.2016.0349
107
LaulagnierK.MottaC.HamdiS.RoyS.FauvelleF.PageauxJ.-F.et al (2004). Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization.Biochem. J.380161–171. 10.1042/bj20031594
108
LeeG. (2002). Spray-drying of proteins.Pharm. Biotechnol.13135–158. 10.1007/978-1-4615-0557-0_6
109
LeeJ. (2014). Trehalose Glycopolymers and Hydrogels for Enhancing Protein Stability.Doctoral dissertation, Los Angeles, CA, Regents of the University of California.
110
LeeM.BanJ. J.ImW.KimM. (2016). Influence of storage condition on exosome recovery.Biotechnol. Bioprocess Eng.21299–304. 10.1007/s12257-015-0781-x
111
LenerT.GiomaM.AignerL.BörgerV.BuzasE.CamussiG.et al (2015). Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.J. Extracell. Vesicles41–31. 10.3402/jev.v4.30087
112
LiJ.ZhangY.LiuY.DaiX.LiW.CaiX.et al (2013). Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis.J. Biol. Chem.28823586–23596. 10.1074/jbc.M113.489302
113
LiX.JiangC.ZhaoJ. (2016). Human endothelial progenitor cells-derived exosomes accelerate cutaneous wound healing in diabetic rats by promoting endothelial function.J. Diabetes Complications30986–992. 10.1016/j.jdiacomp.2016.05.009
114
LiangX.ZhangL.WangS.HanQ.ZhaoR. C. (2016). Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a.J. Cell Sci.1292182–2189. 10.1242/jcs.170373
115
LindemannD.WerleS. B.SteffensD.Garcia-GodoyF.PrankeP.CasagrandeL. (2014). Effects of cryopreservation on the characteristics of dental pulp stem cells of intact deciduous teeth.Arch. Oral Biol.59970–976. 10.1016/j.archoralbio.2014.04.008
116
LindosoR. S.CollinoF.BrunoS.AraujoD. S.Sant’AnnaJ. F.TettaC.et al (2014). Extracellular vesicles released from mesenchymal stromal cells modulate miRNA in renal tubular cells and inhibit ATP depletion injury.Stem Cells Dev.231809–1819. 10.1089/scd.2013.0618
117
LiuS.LiuD.ChenC.HamamuraK.MoshaveriniaA.YangR.et al (2015). MSC transplantation improves osteopenia via epigenetic regulation of notch signaling in lupus.Cell Metab.22606–618. 10.1016/j.cmet.2015.08.018
118
LörinczÁ. M.TimárC. I.MarosváriK. A.VeresD. S.OtrokocsiL.KittelÁ.et al (2014). Effect of storage on physical and functional properties of extracellular vesicles derived from neutrophilic granulocytes.J. Extracell. Vesicles3:25465. 10.3402/jev.v3.25465
119
LötvallJ.HillA. F.HochbergF.BuzásE. I.Di VizioD.GardinerC.et al (2014). Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles.J. Extracell. Vesicles3:26913. 10.3402/jev.v3.26913
120
LouG.SongX.YangF.WuS.WangJ.ChenZ.et al (2015). Exosomes derived from MIR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.J. Hematol. Oncol.81–11. 10.1186/s13045-015-0220-7
121
LvL. L.CaoY.LiuD.XuM.LiuH.TangR. N.et al (2013). Isolation and quantification of MicroRNAs from urinary exosomes/microvesicles for biomarker discovery.Int. J. Biol. Sci.91021–1031. 10.7150/ijbs.6100
122
LydicT. A.TownsendS.AddaC. G.CollinsC.MathivananS.ReidG. E. (2015). Rapid and comprehensive “shotgun” lipidome profiling of colorectal cancer cell derived exosomes.Methods8783–95. 10.1016/j.ymeth.2015.04.014
123
ManconiM.MancaM. L.ValentiD.EscribanoE.HillaireauH.FaddaA. M.et al (2017). Chitosan and hyaluronan coated liposomes for pulmonary administration of curcumin.Int. J. Pharm.525203–210. 10.1016/j.ijpharm.2017.04.044
124
MarotoR.ZhaoY.JamaluddinM.PopovV. L.WangH.KalubowilageM.et al (2017). Effects of storage temperature on airway exosome integrity for diagnostic and functional analyses.J. Extracell. Vesicles6:1359478. 10.1080/20013078.2017.1359478
125
Marquez-CurtisL. A.Janowska-WieczorekA.McGannL. E.ElliottJ. A. W. (2015). Mesenchymal stromal cells derived from various tissues: biological, clinical and cryopreservation aspects.Cryobiology71181–197. 10.1016/j.cryobiol.2015.07.003
126
MartinelloT.BronziniI.MaccatrozzoL.IacopettiI.SampaolesiM.MascarelloF.et al (2010). Cryopreservation does not affect the stem characteristics of multipotent cells isolated from equine peripheral blood.Tissue Eng. Part C Methods16771–781. 10.1089/ten.tec.2009.0512
127
MartinettiD.ColarossiC.BuccheriS.DentiG.MemeoL.VicariL. (2017). Effect of trehalose on cryopreservation of pure peripheral blood stem cells.Biomed. Rep.6314–318. 10.3892/br.2017.859
128
MastersK. (1972). Spray Drying : an Introduction to Principles, Operational Practice, and Applications /K. Masters.London: G. Godwin.
129
MayourianJ.CeholskiD. K.GorskiP.MathiyalaganP.MurphyJ. F.SalazarS. I.et al (2018). Exosomal microRNA-21-5p mediates mesenchymal stem cell paracrine effects on human cardiac tissue contractility.Circ. Res.122933–944. 10.1161/CIRCRESAHA.118.312420
130
MonselA.ZhuY.GennaiS.HaoQ.HuS.RoubyJ.-J.et al (2015). Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice.Am. J. Respir. Crit. Care Med.192324–336. 10.1164/rccm.201410-1765OC
131
MoonJ. H.LeeJ. R.JeeB. C.SuhC. S.KimS. H.LimH. J.et al (2008). Successful vitrification of human amnion-derived mesenchymal stem cells.Hum. Reprod.231760–1770. 10.1093/humrep/den202
132
MorseM. A.GarstJ.OsadaT.KhanS.HobeikaA.ClayT. M.et al (2005). A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.J. Transl. Med.31–8. 10.1186/1479-5876-3-9
133
MottaJ. P. R.Paraguassú-BragaF. H.BouzasL. F.PortoL. C. (2014). Evaluation of intracellular and extracellular trehalose as a cryoprotectant of stem cells obtained from umbilical cord blood.Cryobiology68343–348. 10.1016/j.cryobiol.2014.04.007
134
NaaldijkY.StaudeM.FedorovaV.StolzingA. (2012). Effect of different freezing rates during cryopreservation of rat mesenchymal stem cells using combinations of hydroxyethyl starch and dimethylsulfoxide.BMC Biotechnol.12:49. 10.1186/1472-6750-12-49
135
NamB. M.KimB. Y.JoY. H.LeeS.NemenoJ. G.YangW.et al (2014). Effect of cryopreservation and cell passage number on cell preparations destined for autologous chondrocyte transplantation.Transplant. Proc.461145–1149. 10.1016/j.transproceed.2013.11.117
136
NarayananR.HuangC.RavindranS. (2016). Hijacking the cellular mail: exosome mediated differentiation of mesenchymal stem cells.Stem Cells Int.2016:3808674. 10.1155/2016/3808674
137
NaslundT. I.GehrmannU.QaziK. R.KarlssonM. C. I.GabrielssonS. (2013). Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity.J. Immunol.1902712–2719. 10.4049/jimmunol.1203082
138
NidhiK.IndrajeetS.KhushbooM.GauriK.SenD. J. (2011). Hydrotropy: a promising tool for solubility enhancement: a review.Int. J. Drug Dev. Res.326–33. 10.1002/jps
139
NounouM.El-KhordaguiL. (2005). Influence of different sugar cryoprotectants on the stability and physico-chemical characteristics of freeze-dried 5-fluorouracil plurilamellar vesicles.DARU J. Pharm. Sci.13133–142.
140
OnoM.KosakaN.TominagaN.YoshiokaY.TakeshitaF.TakahashiR. U.et al (2014). Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells.Sci. Signal.7:ra63. 10.1126/scisignal.2005231
141
OpheldersD. R. M. G.WolfsT. G. A. M.JellemaR. K.ZwanenburgA.AndriessenP.DelhaasT.et al (2016). Mesenchymal stromal cell-derived extracellular vesicles protect the fetal brain after hypoxia-ischemia.Stem Cells Transl. Med.5754–763. 10.5966/sctm.2015-0197
142
PachlerK.LenerT.StreifD.DunaiZ. A.DesgeorgesA.FeichtnerM.et al (2017). A Good Manufacturing Practice–grade standard protocol for exclusively human mesenchymal stromal cell–derived extracellular vesicles.Cytotherapy19458–472. 10.1016/j.jcyt.2017.01.001
143
PakravanK.BabashahS.SadeghizadehM.MowlaS. J.Mossahebi-MohammadiM.AtaeiF.et al (2017). MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells.Cell. Oncol.40457–470. 10.1007/s13402-017-0335-7
144
PanyamJ.LabhasetwarV. (2012). Biodegradable nanoparticles for drug and gene delivery to cells and tissue.Adv. Drug Deliv. Rev.6461–71. 10.1016/j.addr.2012.09.023
145
PatelA. R.PatelD. A.ChaudhryS. V. (2011). Mucoadhesive buccal drug delivery system.Int. J. Pharm. Life Sci.2848–856.
146
PembertonT. A.StillB. R.ChristensenE. M.SinghH.SrivastavaD.TannerJ. J. (2012). Proline: mother Natures cryoprotectant applied to protein crystallography.Acta Crystallogr. Sect. D Biol. Crystallogr.681010–1018. 10.1107/S0907444912019580
147
PhinneyD. G.Di GiuseppeM.NjahJ.SalaE.ShivaS.St CroixC. M.et al (2015). Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs.Nat. Commun.6:8472. 10.1038/ncomms9472
148
PirontiG.StrachanR. T.AbrahamD.Mon-Wei YuS.ChenM.ChenW.et al (2015). Circulating exosomes induced by cardiac pressure overload contain functional angiotensin II type 1 receptors.Circulation1312120–2130. 10.1161/CIRCULATIONAHA.115.015687
149
PusicA. D.PusicK. M.ClaytonB. L. L.KraigR. P. (2014). IFNgamma-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.J. Neuroimmunol.26612–23. 10.1016/j.jneuroim.2013.10.014
150
QinY.WangL.GaoZ.ChenG.ZhangC. (2016). Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo.Sci. Rep.6:21961. 10.1038/srep21961
151
Quintanar-GuerreroD.Ganem-QuintanarA.AllémannE.FessiH.DoelkerE. (1998). Influence of the stabilizer coating layer on the purification and freeze-drying of poly(D,L-lactic acid) nanoparticles prepared by an emulsion-diffusion technique.J. Microencapsul.15107–119. 10.3109/02652049809006840
152
RagniE.BanfiF.BarilaniM.CherubiniA.ParazziV.LarghiP.et al (2016). Extracellular vesicle-shuttled mRNA in mesenchymal stem cell communication.Stem Cells351093–1105. 10.1002/stem.2557
153
RanaS.ZollerM. (2013). “The functional importance of tetraspanins in exosomes,” inEmerging Concepts of Tumor Exosome-Mediated Cell-Cell Communication, ed.ZhangH.-G. (Berlin: Springer Science+Business Media), 69–106. 10.1007/978-1-4614-3697-3
154
RaoW.HuangH.WangH.ZhaoS.DumbletonJ.ZhaoG.et al (2015). Nanoparticle-mediated intracellular delivery enables cryopreservation of human adipose-derived stem cells using trehalose as the sole cryoprotectant.ACS Appl. Mater. Interfaces75017–5028. 10.1021/acsami.5b00655
155
RaposoG.StoorvogelW. (2013). Extracellular vesicles: exosomes, microvesicles, and friends.J. Cell Biol.200373–383. 10.1083/jcb.201211138
156
RayS. S.PramanikK.SarangiS. K.JainN. (2016). Serum-free non-toxic freezing solution for cryopreservation of human adipose tissue-derived mesenchymal stem cells.Biotechnol. Lett.381397–1404. 10.1007/s10529-016-2111-6
157
RoyD.GuillonX.LescureF.CouvreurP.BruN.BretonP. (1997). On shelf stability of freeze-dried: poly(methylidene malonate 2.1.2) nanoparticles.Int. J. Pharm.148165–175. 10.1016/S0378-5173(96)04842-9
158
RoyS.AroraS.KumariP.TaM. (2014). A simple and serum-free protocol for cryopreservation of human umbilical cord as source of Wharton’s jelly mesenchymal stem cells.Cryobiology68467–472. 10.1016/j.cryobiol.2014.03.010
159
RubenfeldG. D.CaldwellE.PeabodyE.WeaverJ.MartinD. P.NeffM.et al (2005). Incidence and outcomes of acute lung injury.N. Engl. J. Med.3531685–1693. 10.1056/NEJMoa050333
160
RustP. A.TingeridesC.CannonS. R.BriggsT. W. R.BlunnG. W. (2006). Characterisation of cryopreserved cells freshly isolated from human bone marrow.Cryo Lett.2717–28.
161
SalamaR. O.TrainiD.ChanH.-K.SungA.AmmitA. J.YoungP. M. (2009). Preparation and evaluation of controlled release microparticles for respiratory protein therapy.J. Pharm. Sci.982709–2717. 10.1002/jps.21653
162
SametiM.BohrG.Ravi KumarM. N. V.KneuerC.BakowskyU.NackenM.et al (2003). Stabilisation by freeze-drying of cationically modified silica nanoparticles for gene delivery.Int. J. Pharm.26651–60. 10.1016/S0378-5173(03)00380-6
163
SchaffazickS. R.PohlmannA. R.Dalla-CostaT.GuterresS. S. (2003). Freeze-drying polymeric colloidal suspensions: nanocapsules, nanospheres and nanodispersion. A comparative study.Eur. J. Pharm. Biopharm.56501–505. 10.1016/S0939-6411(03)00139-5
164
SchwarzC.MehnertW. (1997). Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles ( SLN ).Int. J. Pharm.157171–179. 10.1016/S0378-5173(97)00222-6
165
SehgalS.RogersJ. A. (1995). Polymer-coated liposomes: improved liposome stability and release of cytosine arabinoside (Ara-C).J. Microencapsul.1237–47. 10.3109/02652049509051125
166
ShapiroI. M.LandisW. J.RisbudM. V. (2015). Matrix vesicles: are they anchored exosomes?Bone7929–36. 10.1016/j.bone.2015.05.013
167
SheldonH.HeikampE.TurleyH.DragovicR.ThomasP.OonC. E.et al (2010). New mechanism for Notch signaling to endothelium at a distance by delta-like 4 incorporation into exosomes.Blood1162385–2394. 10.1182/blood-2009-08-239228
168
ShenJ. L.HuangY. Z.XuS. X.ZhengP. H.YinW. J.CenJ.et al (2012). Effectiveness of human mesenchymal stem cells derived from bone marrow cryopreserved for 23-25 years.Cryobiology64167–175. 10.1016/j.cryobiol.2012.01.004
169
ShiQ.QianZ.LiuD.SunJ.WangX.LiuH.et al (2017). GMSC-derived exosomes combined with a chitosan/silk hydrogel sponge accelerates wound healing in a diabetic rat skin defect model.Front. Physiol.8:904. 10.3389/fphys.2017.00904
170
Shigemoto-KurodaT.OhJ. Y.KimD.-K.JeongH. J.ParkS. Y.LeeH. J.et al (2017). MSC-derived extracellular vesicles attenuate immune responses in two autoimmune murine models: type 1 diabetes and uveoretinitis.Stem Cell Rep.81214–1225. 10.1016/j.stemcr.2017.04.008
171
ShivakumarS. B.BhartiD.JangS. J.HwangS. C.ParkJ. K.ShinJ. K.et al (2015). Cryopreservation of human wharton’s jelly-derived mesenchymal stem cells following controlled rate freezing protocol using different cryoprotectants; a comparative study.Int. J. Stem Cells8155–169. 10.15283/ijsc.2015.8.2.155
172
SkotlandT.SandvigK.LlorenteA. (2017). Lipids in exosomes: current knowledge and the way forward.Prog. Lipid Res.6630–41. 10.1016/j.plipres.2017.03.001
173
SokolovaV.LudwigA.HornungS.RotanO.HornP. A.EppleM.et al (2011). Colloids and surfaces B : biointerfaces Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy.Colloids Surf. B Biointerfaces87146–150. 10.1016/j.colsurfb.2011.05.013
174
SongY.DouH.LiX.ZhaoX.LiY.LiuD.et al (2017). Exosomal miR-146a contributes to the enhanced therapeutic efficacy of IL-1β-primed mesenchymal stem cells against sepsis.Stem Cells351208–1221. 10.1002/stem.2564
175
StamerW. D.HoffmanE. A.LutherJ. M.HacheyD. L.ScheyK. L. (2011). Protein profile of exosomes from trabecular meshwork cells.J. Proteomics74796–804. 10.1016/j.jprot.2011.02.024
176
StarkB.PabstG.PrasslR. (2010). Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: effects of cryoprotectants on structure.Eur. J. Pharm. Sci.41546–555. 10.1016/j.ejps.2010.08.010
177
StolzenburgL. R.HarrisA. (2017). Microvesicle-mediated delivery of miR-1343: impact on markers of fibrosis.Cell Tissue Res.371325–338. 10.1007/s00441-017-2697-6
178
StormG.BelliotS. O.DaemenT.LasicD. D. (1995). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system.Adv. Drug Deliv. Rev.1731–48. 10.1016/0169-409X(95)00039-A
179
SubediR. K.KangK. W.ChoiH. K. (2009). Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin.Eur. J. Pharm. Sci.37508–513. 10.1016/j.ejps.2009.04.008
180
SubraC.LaulagnierK.PerretB.RecordM. (2007). Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies.Biochimie89205–212. 10.1016/j.biochi.2006.10.014
181
SudresM.MaurerM.RobinetM.BismuthJ.TruffaultF.GirardD.et al (2017). Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model.JCI Insight2:e89665. 10.1172/jci.insight.89665
182
SunH.GlasmacherB.HofmannN. (2012). Compatible solutes improve cryopreservation of human endothelial cells.Cryo Lett.33485–493.
183
TakeuchiH.KojimaH.YamamotoH.KawashimaY. (2000). Polymer coating of liposomes with a modified polyvinyl alcohol and their systemic circulation and RES uptake in rats.J. Control. Release68195–205. 10.1016/S0168-3659(00)00260-1
184
TanC. Y.LaiR. C.WongW.DanY. Y.LimS. -K.HoH. K. (2014). Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models.Stem Cell Res. Ther.5:76. 10.1186/scrt465
185
TanJ. L.LauS. N.LeawB.NguyenH. P. T.SalamonsenL. A.SaadM. I.et al (2018). Amnion epithelial cell-derived exosomes restrict lung injury and enhance endogenous lung repair.Stem Cells Transl. Med.7180–196. 10.1002/sctm.17-0185
186
TanakaK.KawamuraM.OtakeK.ToiyamaY.OkugawaY.InoueY.et al (2014). Trehalose does not affect the functions of human neutrophils in vitro.Surg. Today44332–339. 10.1007/s00595-013-0625-2
187
TheryC.BoussacM.VeronP.Ricciardi-CastagnoliP.RaposoG.GarinJ.et al (2001). Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles.J. Immunol.1667309–7318. 10.4049/jimmunol.166.12.7309
188
TheryC.RegnaultA.GarinJ.WolfersJ.ZitvogelL.Ricciardi-CastagnoliP.et al (1999). Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73.J. Cell Biol.147599–610. 10.1083/jcb.147.3.599
189
ThirumalaS.GimbleJ. M.DevireddyR. V. (2010). Evaluation of methylcellulose and dimethyl sulfoxide as the cryoprotectants in a serum-free freezing media for cryopreservation of adipose-derived adult stem cells.Stem Cells Dev.19513–522. 10.1089/scd.2009.0173
190
TianY.LiS.SongJ.JiT.ZhuM.AndersonG. J.et al (2014). A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy.Biomaterials352383–2390. 10.1016/j.biomaterials.2013.11.083
191
TkachM.ThéryC. (2016). Communication by extracellular vesicles: where we are and where we need to go.Cell1641226–1232. 10.1016/j.cell.2016.01.043
192
TomasoniS.LongarettiL.RotaC.MorigiM.ContiS.GottiE.et al (2013). Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells.Stem Cells Dev.22772–780. 10.1089/scd.2012.0266
193
TradF. S.TonerM.BiggersJ. D. (1999). Effects of cryoprotectants and ice-seeding temperature on intracellular freezing and survival of human oocytes.Hum. Reprod.141569–1577. 10.1093/humrep/14.6.1569
194
ValadiH.EkströmK.BossiosA.SjöstrandM.LeeJ. J.LötvallJ. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.Nat. Cell Biol.9654–659. 10.1038/ncb1596
195
VallabhaneniK. C.PenfornisP.DhuleS.GuillonneauF.AdamsK. V.Yuan MoY.et al (2015). Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites.Oncotarget64953–4967. 10.18632/oncotarget.3211
196
Van BackstalP.-J.De BeerT.CorverJ. (2017). A continuous and controlled pharmaceutical freeze-drying technology for unit doses.Eur. Pharm. Rev.2251–53. 10.1016/j.ijpharm.2018.02.003
197
van NielG.D’AngeloG.RaposoG. (2018). Shedding light on the cell biology of extracellular vesicles.Nat. Rev. Mol. Cell Biol.19213–228. 10.1038/nrm.2017.125
198
van NielG.Porto-CarreiroI.SimoesS.RaposoG. (2006). Exosomes: a common pathway for a specialized function.J. Biochem.14013–21. 10.1093/jb/mvj128
199
ViaudS.TermeM.FlamentC.TaiebJ.AndréF.NovaultS.et al (2009). Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Rα.PLoS One4:e4942. 10.1371/journal.pone.0004942
200
VrijsenK. R.MaringJ. A.ChamuleauS. A. J.VerhageV.MolE. A.DeddensJ. C.et al (2016). Exosomes from cardiomyocyte progenitor cells and mesenchymal stem cells stimulate angiogenesis via EMMPRIN.Adv. Healthc. Mater.52555–2565. 10.1002/adhm.201600308
201
WangB.YaoK.HuuskesB. M.ShenH. -H.ZhuangJ.GodsonC.et al (2016). Mesenchymal stem cells deliver exogenous MicroRNA-let7c via exosomes to attenuate renal fibrosis.Mol. Ther.241290–1301. 10.1038/mt.2016.90
202
WangH.-Y.LunZ.-R.LuS.-S. (2011). Cryopreservation of umbilical cord blood-derived mesenchymal stem cells without dimethyl sulfoxide.Cryo Lett.3281–88.
203
WangY.ZhangL.LiY.ChenL.WangX.GuoW.et al (2015). Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium.Int. J. Cardiol.19261–69. 10.1016/j.ijcard.2015.05.020
204
WillisonJ. H. M.RoweA. J. (1980). Replica, Shadowing and Freeze-Etching Techniques.Amsterdam: Elsevier.
205
WoodsE. J.PerryB. C.HockemaJ. J.LarsonL.ZhouD.GoebelW. S. (2010). Optimized cryopreservation method for human dental pulp-derived stem cells and their tissues of origin for banking and clinical use.Cryobiology59150–157. 10.1016/j.cryobiol.2009.06.005
206
WuY.DengW.BabbM.CancerR.VirginiaW.BiologyC. (2015a). Exosomes: improved methods to characterize their morphology, RNA content, and surface protein biomarkers.Analyst1406631–6642. 10.1039/c5an00688k
207
WuY.DengW.KlinkeD. J. (2015b). Exosomes: improved methods to characterize their morphology, RNA content, and surface protein biomarkers.Analyst1406631–6642. 10.1039/c5an00688k
208
XinH.LiY.BullerB.KatakowskiM.ZhangY.WangX.et al (2012). Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth.Stem Cells301556–1564. 10.1002/stem.1129.Exosome-Mediated
209
XinH.LiY.LiuZ.WangX.ShangX.CuiY.et al (2013). MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles.Stem Cells312737–2746. 10.1002/stem.1409
210
XuX.LiuY.CuiZ.WeiY.ZhangL. (2012). Effects of osmotic and cold shock on adherent human mesenchymal stem cells during cryopreservation.J. Biotechnol.162224–231. 10.1016/j.jbiotec.2012.09.004
211
YangT.MartinP.FogartyB.BrownA.SchurmanK.PhippsR.et al (2015). Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio.Pharm. Res.322003–2014. 10.1007/s11095-014-1593-y
212
YuB.KimH. W.GongM.WangJ.MillardR. W.WangY.et al (2015). Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection.Int. J. Cardiol.182349–360. 10.1016/j.ijcard.2014.12.043
213
ZhangB.WangM.GongA.ZhangX.WuX.ZhuY.et al (2015a). HucMSc-exosome mediated-Wnt4 signaling is required for cutaneous wound healing.Stem Cells332158–2168. 10.1002/stem.1771
214
ZhangB.WuX.ZhangX.SunY.YanY.ShiH.et al (2015b). Human umbilical cord mesenchymal stem cell exosomes enhance angiogenesis through the Wnt4/beta-catenin pathway.Stem Cells Transl. Med.4513–522. 10.5966/sctm.2014-0267
215
ZhangB.YinY.LaiR. C.LimS. K. (2014a). Immunotherapeutic potential of extracellular vesicles.Front. Immunol.5:518. 10.3389/fimmu.2014.00518
216
ZhangB.YinY.LaiR. C.TanS. S.ChooA. B. H.LimS. K. (2014b). Mesenchymal stem cells secrete immunologically active exosomes.Stem Cells Dev.231233–1244. 10.1089/scd.2013.0479
217
ZhangG.ZouX.MiaoS.ChenJ.DuT.ZhongL.et al (2014c). The anti-oxidative role of micro-vesicles derived from human Wharton-Jelly mesenchymal stromal cells through NOX2/gp91(phox) suppression in alleviating renal ischemia-reperfusion injury in rats.PLoS One9:e92129. 10.1371/journal.pone.0092129
218
ZhangJ.LiuX.LiH.ChenC.HuB.NiuX.et al (2016). Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signaling pathway.Stem Cell Res. Ther.7:136. 10.1186/s13287-016-0391-3
219
ZhaoB.ZhangY.HanS.ZhangW.ZhouQ.GuanH.et al (2017). Exosomes derived from human amniotic epithelial cells accelerate wound healing and inhibit scar formation.J. Mol. Histol.48121–132. 10.1007/s10735-017-9711-x
220
ZhuY. G.FengX. M.AbbottJ.FangX. H.HaoQ.MonselA.et al (2014). Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice.Stem. Cells32116–125. 10.1002/stem.1504.
221
ZimmermannE.MullerR. H.MaderK. (2000). Influence of different parameters on reconstitution of∖rlyophilized SLN.Int. J. Pharm.196211–213. 10.1016/S0378-5173(99)00424-X
Summary
Keywords
nanomedicine, exosomes, extracellular vesicles, biomaterials, cryopreservation, regenerative medicine, biologics
Citation
Kusuma GD, Barabadi M, Tan JL, Morton DAV, Frith JE and Lim R (2018) To Protect and to Preserve: Novel Preservation Strategies for Extracellular Vesicles. Front. Pharmacol. 9:1199. doi: 10.3389/fphar.2018.01199
Received
03 August 2018
Accepted
28 September 2018
Published
29 October 2018
Volume
9 - 2018
Edited by
Lei Xi, Virginia Commonwealth University, United States
Reviewed by
Sudheer Kumar Ravuri, Steadman Philippon Research Institute, United States; Guo-Chang Fan, University of Cincinnati, United States
Updates
Copyright
© 2018 Kusuma, Barabadi, Tan, Morton, Frith and Lim.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rebecca Lim, Rebecca.Lim@hudson.org.au
†These authors have contributed equally to this work
This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.